Safety profile of novel oral poliovirus vaccine type 2

Key Points

• To assess the safety profile and immunogenicity of a novel oral poliovirus vaccine type 2.
• Randomized trial design
• Assessment of vaccine-related adverse events
• Evaluation of seroconversion rates post-vaccination
• Low incidence of adverse events reported in the vaccine group
• High seroconversion rate of 90% in vaccinated individuals
• No serious adverse events linked to the novel vaccine type 2